- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04197141
Gehypofractioneerde Whole-Pelvis Radiotherapie (WPRT) versus conventioneel gefractioneerde WPRT bij prostaatkanker (HOPE)
Wordt Hypofractionated Whole-Pelvis Radiotherapy (WPRT) even goed verdragen als conventioneel gefractioneerde WPRT bij prostaatkankerpatiënten? (HOPE-proef)
The purpose of this research study is to determine if 5 (five) fractions of external radiotherapy with higher radiation doses per fraction to the pelvis leads to similar results to the standard of care external radiotherapy treatment that is comprised of 25 fractions of external radiotherapy with lower radiation doses per fraction to the pelvis.
This study aims to investigate the impact in quality of life associated with hypofractionated Whole Pelvis Radiotherapy (WPRT) in comparison to conventionally-fractionated WPRT in patients with unfavorable-intermediate and high-risk prostate cancers. This information is valuable as hypofractionated WPRT is a more attractive and convenient treatment approach, and may become the new standard of care if proven to be well-tolerated and effective. Therefore, this study aims to provide a more rational justification for use of hypofractionated WPRT in future larger randomized trials by comparing this strategy with the current standard of care. This study will also provide an initial understanding of the toxicity profile and cancer control associated with hypofractionated WPRT and High Dose Rate Brachytherapy (HDR-BT).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- BC Cancer
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- London Regional Cancer Program of the Lawson Health Research Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 or older
- Study Informed Consent provided
- Pathologically proven diagnosis of prostatic adenocarcinoma
- Unfavorable intermediate risk [with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification [Prostatic Specific Antigen (PSA) > 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10]
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy
Exclusion Criteria:
- Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
- Plan for adjuvant docetaxel post-radiotherapy
- Serious medical comorbidities or other contraindications to HDR-BT
- Presence of inflammatory bowel disease
- Presence of connective tissue disease
- Medically unfit for general anesthesia
- Unable or unwilling to complete questionnaires
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Conventionally-fractionated WPRT
15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician. |
Total dose: 45 Gy in 25 fractions WPRT |
|
Experimenteel: Hypofractionated WPRT
15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician. |
Total dose: 25 Gy in 5 fractions WPRT |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quality of Life (QOL) - late bowel function as measured by the EPIC questionnaire
Tijdsspanne: I year post treatment (approximately 3 years and 2 months)
|
Late bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score. |
I year post treatment (approximately 3 years and 2 months)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quality of Life - acute urinary and sexual QOL as measured by the EPIC questionnaire
Tijdsspanne: 6 weeks post treatment (approximately 2 years and 3 months)
|
Acute urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) urinary and sexual domains. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score. |
6 weeks post treatment (approximately 2 years and 3 months)
|
|
Quality of Life - acute bowel toxicity as measured by the EPIC questionnaire
Tijdsspanne: 6 weeks post treatment (approximately 2 years and 3 months)
|
Acute bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) approximately 6 weeks after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score. |
6 weeks post treatment (approximately 2 years and 3 months)
|
|
Quality of Life - late bowel bother as measured by the EPIC questionnaire
Tijdsspanne: I year post treatment (approximately 3 years and 2 months)
|
Late bowel bother as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score. |
I year post treatment (approximately 3 years and 2 months)
|
|
Quality of Life - late urinary and sexual QOL as measured by the EPIC questionnaire
Tijdsspanne: I year post treatment (approximately 3 years and 2 months)
|
Late urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC). The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score. |
I year post treatment (approximately 3 years and 2 months)
|
|
International Prostate Symptom Score (IPSS)
Tijdsspanne: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
|
International Prostate Symptom Score (IPSS) as reported by the patient at 6 weeks, 1 year, and 2 years post treatment. The IPSS is a tool used for monitoring symptoms of prostate enlargement (benign prostatic hyperplasia). There are 7 questions related to urinary function. Responses are on a scale from 0 (best) to 5 (worst). Responses are added to come up with a total score, measuring if the patient is mildly symptomatic, moderately symptomatic, or severely symptomatic. There is 1 quality of life question related to urinary symptoms. Responses are on a scale from 0 (best) to 6 (worst). |
6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
|
|
Toxicity - urinary, bowel, and sexual as measured by CTCAE version 4.0
Tijdsspanne: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
|
Urinary, bowel, and sexual toxicity will be measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4, at 6 weeks, 1 year, and 2 years post treatment. |
6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
|
|
Prostatic Specific Antigen (PSA) curve
Tijdsspanne: 4 years post treatment (approximately 6 years and 2 months)
|
PSA curve at 4 years post-treatment. |
4 years post treatment (approximately 6 years and 2 months)
|
|
Prostatic Specific Antigen (PSA) Nadir
Tijdsspanne: 4 years post treatment (approximately 6 years and 2 months)
|
PSA nadir at 4 years post-treatment. |
4 years post treatment (approximately 6 years and 2 months)
|
|
Cost Effectiveness of Hypofractionated WPRT
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
Cost effectiveness analysis of the hypofractionated arm in comparison to the conventionally fractionated treatment arm. |
End of study (approximately 7 years and 2 months)
|
|
Overall Survival
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to death from any cause. |
End of study (approximately 7 years and 2 months)
|
|
Biochemical Failure-Free Survival
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to biochemical failure (based on the Phoenix definition) or death from any cause, whichever occurs first. |
End of study (approximately 7 years and 2 months)
|
|
Freedom from Local Failure
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to first local failure. |
End of study (approximately 7 years and 2 months)
|
|
Freedom from Regional Failure
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to first regional failure. |
End of study (approximately 7 years and 2 months)
|
|
Androgen Deprivation Therapy Free Survival
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to start of salvage ADT, death or last follow-up. |
End of study (approximately 7 years and 2 months)
|
|
Metastasis Free Survival
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to development of metastasis, death or last follow-up. |
End of study (approximately 7 years and 2 months)
|
|
Prostate Cancer Free Survival
Tijdsspanne: End of study (approximately 7 years and 2 months)
|
The time from randomization to death attributed to prostate cancer. |
End of study (approximately 7 years and 2 months)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Lucas C Mendez, MD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HOPE Trial
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .